Moderna: A Long-Term Business Owner's Perspective

What stage is this industry in? Moderna is not in a single industry, but in two markets with completely different rhythms: on one side is the respiratory vaccine market, which has entered a post-pandemic, seasonal, policy-sensitive phase; on the other is the individualized cancer vaccine and rare-disease therapy market, which still carries high R&D risk and has not yet settled into a commercial form. The social need for respiratory disease prevention exists over the long term. The CDC still preserves an individualized decision-making pathway for COVID vaccination in the 2025-2026 season, and the disease burden from RSV and flu among older adults remains significant; but U.S. federal vaccine policy changed sharply several times in 2025-2026, showing that "medical need exists" does not equal "a stable market exists."

Who are the main competitors? In COVID, Moderna directly faces approved vaccines from Pfizer/BioNTech and Novavax. In flu and combination vaccines, it faces large traditional vaccine manufacturers and is trying to win share through mRNA's update speed and the convenience of combination products. In cancer vaccines, it competes with multiple global immuno-oncology companies, but the most important reality is this: even if clinical data are good, commercialization still depends on the maturity of insurance coverage, clinical workflows, capacity, and companion diagnostic systems. BioNTech reported 2025 revenue of EUR2.870 billion, of which COVID vaccine revenue was EUR1.995 billion, and had EUR17.236 billion of cash, cash equivalents, and security investments combined; this shows that the "mRNA platform" does not belong only to Moderna.

If the stock market closed for five years, would I be willing to hold it? At today's price, I would not treat it as a five-year closed-market holding that lets me sleep well. The reason is not weak technology. It is that the value-realization path over the next five years depends too much on a small number of approval and clinical milestones. This looks more like a "research asset company with potential" than a good company that has already entered a stable rent-collecting phase. Business understandability score: 3/5.

Moat and Management

Moat Assessment

Moderna has a moat, but it is not wide enough and not yet stable enough.

Start with what it has. 【Fact】 The company has indeed demonstrated execution ability in the mRNA platform, LNP delivery, process scale-up, rapid variant updates, global regulatory submissions, and production organization; in 2025-2026, it continued advancing projects such as mNEXSPIKE, mCOMBRIAX, mRNA-1010, norovirus, and intismeran into clearer registration or Phase 3 stages. 【Inference】 For a new entrant, replicating Moderna's combined capabilities in "platform + process + parallel multi-project execution + global submissions" would usually require many years and several billion dollars of capital.

But then there is what it does not have. It has almost no network effects and no strong switching costs: doctors and payers are not permanently locked in because they "used Moderna"; vaccine products depend more on efficacy, safety, recommendation language, supply reliability, and payment coverage. Its brand moat is limited, because the market ultimately looks at clinical data and regulatory labels. Its channel moat is also not strong, because wholesalers and government purchasers do not naturally serve only Moderna. Its pricing power is limited, especially in public health and seasonal vaccines, where prices are more easily affected by tenders, reimbursement, competing products, and policy.

Patents and regulatory barriers are where it most resembles a moat, but there are two sides here as well. 【Fact】 In 2026, the company reached a global settlement with Arbutus/Genevant: it will pay $950 million in Q3, and if the relevant appeal goes against it, there may be an additional payment of up to $1.3 billion; the benefit is that Moderna obtained a global non-exclusive LNP license for infectious-disease indications with no future royalties, removing a major uncertainty. The downside is that this also reminds investors that Moderna's moat is not an "undisputed exclusive river," but one that must be reinforced through litigation, settlement, and licensing.

So my assessment is: Brand advantage: weak. Cost advantage: moderately weak. In theory, the mRNA platform can shorten development cycles, but it does not create an absolute low-cost position against mature large manufacturers. Scale advantage: moderate. Especially in process, submissions, and global partnerships. Network effects: none. Switching costs: weak. Channel advantage: weak. Patent/regulatory barriers: moderate. Data advantage: moderate. A large amount of real-world and clinical data helps, but has not formed an irreplaceable closed loop. Corporate culture/operating capability: moderately strong. Advancement speed and cost reduction reflect execution ability. Capital allocation ability: moderately weak. R&D allocation has bright spots, but the buyback timing was an obvious mistake.

Overall judgment: the moat is "narrow but real," not "wide and stable"; it has narrowed in COVID compared with 2021, while in oncology and combination vaccines there is still room to widen, but that must wait for Phase 3 results and commercialization to truly deliver. Moat strength score: 2/5.

Management and Capital Allocation

Is management trustworthy? My answer is: basically credible, but the capital allocation score can only be considered average.

The positive side is clear. 【Fact】 CEO Stéphane Bancel directly and indirectly holds about 30.65 million shares, representing about 7.6% of the company; all executives, directors, and director nominees together hold about 10.8%. The 2026 proxy statement shows that the chair and CEO roles are separated; the company did not grant retention-type special equity awards to executives in 2025, froze executive base salaries and target bonus percentages in 2026, and explicitly excluded executive committee members and directors from the 2025 employee option exchange program. 【Inference】 This suggests that executives are not completely detached from shareholders, and the governance framework is not poor.

Management has also achieved something operationally. In Q1 2026, the company's adjusted cash costs fell 26% year over year, and it set a 2026 adjusted cash cost target of about $4.2 billion; the 2024 shareholder letter also stated that cash operating costs by the end of 2024 had fallen nearly 25% from the prior year. This shows that management at least recognizes that post-pandemic Moderna cannot live with a pandemic-era cost structure.

The real drag is capital allocation timing. In 2022 and 2023, the board repurchased about 31 million shares in total, spending about $4.482 billion at an average repurchase price of about $143 per share; by the end of May 2026, the share price was about $47.19. From the plainest owner perspective, this was clear value destruction: the company used a huge amount of cash mainly to buy back stock when it was overvalued, not when it was significantly undervalued. Later, in 2024-2026, the company stopped repurchasing, while at the end of 2025 it introduced a $600 million high-interest floating-rate loan and retained up to $1.5 billion of credit capacity. That contrast is glaring.

One more point needs a cool-headed view: stock-based compensation is not low. Stock-based compensation expense was $483 million in 2025, and unrecognized stock-based compensation cost was still $633 million, to be recognized over an average of about 2.1 years; share count rose from 382 million shares at the end of 2023 back to 394 million shares at the end of 2025, and had reached 396.59 million shares in March 2026. In other words, the company once bought back stock at high prices while continuing to give back part of the buyback effect through equity compensation.

So my conclusion is: Management integrity and execution: moderately above average. Capital allocation: moderately below average. Management and capital allocation score: 3/5.

Financial Quality and Owner Earnings

Key Financial Facts

The table below summarizes Moderna's financial trajectory using reported figures for 2020-2025. You will see a very important fact: this is not a linear growth story, but a financial curve of "pandemic windfall profits -> demand collapse -> cash-burning transition."

Data sources: Moderna's consolidated statements of operations, cash flows, and balance sheets in its 2021, 2023, and 2025 10-K filings; "ending cash and investments" is calculated as the sum of cash, cash equivalents, and short- and long-term investments.

From this table, I draw six conclusions.

First, revenue is not stable compounding, but a retreat after a one-time peak. Revenue was in the $18.5 billion to $19.3 billion range in 2021-2022, but only $1.944 billion in 2025. Peak profits did not turn into a meaningfully stable post-pandemic revenue platform.

Second, peak margins were not a structural norm. Operating margin was about 72% in 2021 and about 49% in 2022; but in 2023-2025, operating margins were about -61.9%, -121.9%, and -158.1%, respectively. This clearly shows that the historical high margins mainly came from a special pandemic-period profit pool, not from a business structure that can be reproduced over the long term in normal competition.

Third, cash flow quality has not been better than profit in recent years; both have deteriorated together. In 2023-2025, operating cash flow was -$3.118 billion, -$3.004 billion, and -$1.873 billion, respectively, while free cash flow was -$3.825 billion, -$4.055 billion, and -$2.065 billion. In other words, the losses of the past three years were not "just accounting losses"; they were largely real cash outflows.

Fourth, the profit-to-cash-flow dynamics at the pandemic peak are not fully repeatable. Free cash flow exceeded net income in 2021, partly because of customer deposits and deferred revenue; in 2022, operating cash flow was far below net income, largely because deferred revenue decreased by $4.157 billion. 【Inference】 This means peak-period profits included the benefits of public-health purchasing rhythms and prepayment structures, and should not be mechanically extrapolated.

Fifth, the balance sheet is still strong, but it is being consumed. At the end of 2025, the company had $8.135 billion of cash and investments; by Q1 2026, management's earnings materials gave "cash and investments" of $7.5 billion. Long-term debt was $590 million at the end of 2025; in addition, in Q1 2026 the Arbutus/Genevant settlement created a $950 million accrued settlement payable, with up to $1.3 billion of contingent additional payment not yet accrued. Liquidity remains strong, but the cushion has clearly become thinner.

Sixth, the financial statements currently do not show obvious "accounting fraud" red flags, but they do show "operating forecasting error" red flags. I am more worried about inventory, returns, raw-material purchase commitments, and capacity planning judgments than about earnings embellishment. The repeated large inventory write-downs and idle capacity charges in 2023-2025 show more about difficult demand forecasting and poor business-model flexibility than about profit manipulation.

Owner Earnings

Using a Buffett-style Owner Earnings approach for Moderna, the conclusion is very plain: current real distributable cash flow remains negative.

I use 2025 as the conservative baseline because it is less affected by one-time litigation accounting treatment than Q1 2026.

• Net income: -$2.822 billion.

• Add back non-cash items: depreciation and amortization of $215 million; stock-based compensation of $483 million; other non-cash items of $77 million.

• Working capital changes: 2025 operating cash flow already includes changes in receivables, prepaids, inventory, payables, deferred revenue, and other items, resulting in -$1.873 billion.

• Maintenance capex: The company does not disclose "maintenance capex." 【Assumption】 Since capex fell to $192 million in 2025 after major construction in 2024, I conservatively assume that about $125 million of it was maintenance capex. This assumption is not a fact; it is a valuation assumption.

On that basis, I give a conservative Owner Earnings estimate:

Owner Earnings ≈ operating cash flow - maintenance capex ≈ -$1.873 billion - $125 million = -$1.998 billion.

This number implies three things.

First, current Owner Earnings are negative, and not slightly negative. Second, the current share price cannot be valued meaningfully by applying a positive multiple to Owner Earnings, because the denominator is still negative. Third, when the market prices Moderna today, it is essentially not paying for a "current cash cow," but for the option value of "future respiratory product portfolio + cancer vaccine + long-term platform value."

Q1 2026 data further supports this. The company reported Q1 total revenue of $389 million, a GAAP net loss of $1.3 billion, and a loss of about $500 million even after excluding the Arbutus litigation impact; meanwhile, because the settlement payable had not yet been paid in the cash flow statement but had already been recorded as a payable, operating cash flow showed only a $630 million net outflow. 【Inference】 If the short-term "boost" to operating cash flow from the $950 million accrued settlement liability is excluded, the underlying cash burn is actually heavier than it appears.

The conclusion is simple: Moderna today is not yet a mature good business that can steadily "spit out real cash." It is a company using its cash reserves to buy time for its future product line.

Valuation and Margin of Safety

Before looking at valuation, first look at what the market currently pays for it.

As of 2026-05-30 (Tokyo time), MRNA's latest price was about $47.19 per share, with a market capitalization of about $18.64 billion; static PE was negative, which means the traditional "low PE value stock" framework does not apply here.

Owner Earnings DCF

Because current Owner Earnings are negative, I use a staged recovery DCF rather than directly applying a multiple to some "normal-year profit." Everything below is an 【Assumption】, not a fact.

The underlying inputs for these ranges mainly depend on the company's current cash reserves, real cash burn in 2025-2026, the 2026 revenue growth guidance of up to 10%, the path toward targeted cash breakeven in 2028, and assessments of key pipeline milestones.

My core explanation is:

• The bear scenario only assigns value to "net cash + an unstable respiratory franchise."

• The base scenario recognizes "flu, combination vaccines, continued mNEXSPIKE uptake + partial pipeline delivery."

• The bull scenario requires individualized cancer vaccines and other assets to truly cross the commercialization threshold.

Therefore, the current $47.19 sits in the lower-middle part of my "base intrinsic value range," but is meaningfully above the bear intrinsic value. This means: it is not absurdly expensive, but it is certainly not "cheap enough to have a buffer even if I make a mistake" in the Buffett sense.

Relative Valuation

The biggest difficulty in applying relative valuation to Moderna is that many peers are also in a "post-COVID re-rating" phase, and earnings bases are not comparable.

But two comparisons are valuable.

First, compared with BioNTech. BioNTech reported 2025 revenue of EUR2.870 billion, of which COVID vaccine revenue was EUR1.995 billion; at the end of 2025, cash, cash equivalents, and security investments totaled EUR17.236 billion. Moderna's 2025 revenue was $1.944 billion, and Q1 2026 cash and investments were about $7.5 billion. 【Inference】 On an enterprise value basis, Moderna is not obviously cheaper than BioNTech. In fact, despite weaker current cash generation, the market still gives it a meaningful platform and pipeline premium.

Second, compared with large mature pharmaceutical companies. Pfizer's current share price is about $26.18, 2025 full-year revenue was $62.579 billion, and it expects about $5.0 billion from COVID products in 2026; Merck's current share price is about $118.72. Although these companies also face patent cliffs and pipeline risk, they have many mature products that are already printing cash, while Moderna has not yet returned to stable profitability. 【View】 For conservative investors, rather than treating $47 MRNA as a "value stock," it is better to recognize that it is actually more like a high-volatility innovative-drug option.

Asset and Liquidation Value

From a cooler "liquidation asset" perspective, Moderna's base value is mainly cash.

• Q1 2026 cash and investments: $7.5 billion.

• Long-term debt at the end of 2025: $590 million.

• Recognized litigation settlement payable: $950 million, payable in Q3.

• Maximum contingent additional payment: $1.3 billion, not currently accrued.

Roughly, after deducting debt and the recognized settlement payable, net cash is about $5.95 billion, corresponding to about $15 per share; if the worst case requires another $1.3 billion additional payment, the net cash cushion would fall to about $4.65 billion, corresponding to about $12 per share. This shows that the company does not have an "immediate balance-sheet risk," but it also shows that at least more than two thirds of the current share price is not cash, but money investors are prepaying for future product success.

Margin of Safety Conclusion

My valuation conclusion can be summarized as follows:

Therefore, my answer to "is the margin of safety sufficient?" is: No. For a balanced but conservative investor, the most fragile assumption is not the discount rate. It is "flu/combination vaccines will scale on schedule, cancer vaccines will eventually succeed, and shareholders will not be diluted along the way by policy and cash burn." If any one of these breaks, the current price does not leave much room for error.

Risks, Bear Case, and Opportunity Comparison

Most Important Risks

Competition risk. COVID, flu, and RSV are not "winner takes all" markets, and Moderna is not facing weak opponents; BioNTech still has strong cash and platform capability, Pfizer has a mature commercial system, and Novavax is catching up through partnerships with companies such as Sanofi.

Technology substitution and clinical failure risk. Moderna's true valuation ceiling probably comes from oncology projects such as intismeran, and that still requires Phase 3 data and commercialization validation. Encouraging five-year Phase 2 data do not mean Phase 3 will definitely succeed.

Regulatory and policy risk. In 2025-2026, U.S. COVID vaccine recommendation language, policies for children and pregnant women, shared-decision frameworks, and strain selection for 2026-2027 all showed an unstable policy environment; mRNA-1010's application also experienced a refusal-to-file followed by renewed review. This type of risk can directly change market size, approval timing, and the multiple investors are willing to pay.

Financial and cash burn risk. Although the company still has cash, it recorded large negative free cash flow continuously in 2023-2025, and still needs to pay the $950 million settlement in 2026. If core products underperform expectations in 2026-2028, cash on the balance sheet will continue to decline, pushing the company toward a less favorable financing or dilution environment.

Management and capital allocation risk. The buyback at high prices is an error that has already happened, not a theoretical risk. If the company continues to take aggressive capital actions when value is unclear, shareholder returns may continue to suffer.

Intellectual property and litigation risk. Arbutus/Genevant risk has eased substantially, but it has not gone to zero; the company has also disclosed litigation related to CureVac, GSK, Northwestern, and others.

Strongest Bear Case

If I were short, I would say this:

Moderna's pandemic windfall is over, and the existing business has not proved that it can still make money steadily after normalization; the so-called "platform value" has been talked about by the market for years, but large-scale, sustainable, non-COVID cash flow has not yet appeared. Buying it now is not buying certain cash flow. It is betting on approvals, policy, and cancer vaccines, and those are not things conservative investors should bet on with a high allocation.

I think this is a strong bear case that cannot be easily dismissed.

What facts would make me admit I was wrong?

• mRNA-1010 is not approved, or commercialization falls short after approval.

• mCOMBRIAX launches slowly in the EU and cannot prove that the convenience of combination vaccines can turn into profit.

• intismeran Phase 3 melanoma data are poor, or the commercialization path is clearly difficult.

• Cash continues to fall rapidly in 2026-2027 with no clear path toward near-breakeven in 2028.

• New major litigation or regulatory actions further compress the space for mRNA products.

The largest permanent capital loss scenario is not a short-term halving of the share price. It is: respiratory commercialization misses expectations + oncology projects fail + the regulatory environment worsens + cash keeps burning, ultimately forcing financing or major dilution at low prices. That would cause today's "platform dream premium" to truly evaporate.

Comparison with Other Opportunities

Compared with the strongest same-track competitor BioNTech, Moderna is not obviously cheaper. Instead, despite weaker current cash generation, the market is still willing to give it a higher future-delivery premium.

Compared with the broad index proxy SPY, Moderna must offer significantly higher expected long-term returns to compensate for its single-company, single-platform, few-key-events-driven risk. But under my base valuation, the expected return at the current price is not clearly superior to a diversified index.

Compared with risk-free or high-grade bond yields, at the end of May 2026 the U.S. 10-year Treasury yield was about 4.45%, while Moody's Aaa corporate bond yield was about 5.50%. My estimate of Moderna's base long-term annualized return at the current price is only low single digits to mid single digits. 【Inference】 For conservative capital, the risk compensation is insufficient.

So the answer to "does it deserve my capital?" is: If you can hold only 5 assets, Moderna should not enter a balanced but conservative portfolio. If you have a dedicated innovative-drug or high-volatility growth sleeve, a small watch position is reasonable, but it is not a stock to overweight now.

Checklist and Final Investment Conclusion

Investment Checklist

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Moderna is not a "mature good business" that has already proved it can distribute cash steadily over the long term, but a high-uncertainty innovative-drug company that still needs to realize platform value through a few key approval and clinical events.

【Core Bull Points】

• The company truly has mRNA platform, process, global submission, and production organization capabilities; it is not an empty narrative.

• Cash and investments remain around $7.5 billion, so there is no near-term survival crisis.

• mCOMBRIAX has been approved in the EU, mRNA-1010 has an August 5, 2026 PDUFA date, and near-term milestones are dense.

• intismeran's long-term Phase 2 data are positive; if Phase 3 succeeds, the valuation logic would change materially.

• The Arbutus/Genevant litigation settlement resolved a major intellectual-property overhang, with no ongoing future royalty.

【Core Bear Points】

• The existing business has not yet formed stable, predictable, distributable free cash flow.

• Peak profits have been proved unsustainable, and the post-pandemic revenue platform is far smaller than the market once expected.

• U.S. vaccine policy and regulatory language became clearly more unstable in 2025-2026.

• Large buybacks at high prices exposed capital allocation flaws.

• At the current share price, the margin of safety is not thick enough, and investment returns depend more on the optimistic scenario.

【Key Assumptions】

• mRNA-1010 can be approved on schedule and contribute material revenue.

• mCOMBRIAX in the EU and elsewhere is not merely "approved," but can truly generate vaccination volume and profit.

• The company can at least approach cash breakeven around 2028.

• At least one late-stage project such as intismeran becomes a blockbuster-scale asset.

• The regulatory environment in the U.S. and major markets does not continue to deteriorate materially.

【Ideal/Fair Buy Price】 I would tend to view $28-38 per share as a more comfortable buy range. The basis is that this range gives me roughly a 25% discount to the "base intrinsic value" of $40-55, and is also closer to the overlap between "conservative value" and "base value."

【Target Holding Period】 At least 5-10 years, on the condition that you are willing to treat it as an innovative-drug investment that needs continuous validation, not as a consumer-products business you can buy and then ignore.

【Expected Annualized Return】 This is based on my own valuation scenarios, not sell-side consensus expectations:

• Bear scenario: -4% to -7% per year.

• Base scenario: 1% to 4% per year.

• Bull scenario: 8% to 12% per year. The ranges are so wide because the company's value depends heavily on a few binary events.

【Maximum Loss Risk】 If the respiratory product portfolio does not commercialize smoothly, oncology Phase 3 misses the mark, regulation suppresses the mRNA track, and cash continues to flow out, a permanent loss of more than 50% from the current share price is not impossible; in an extreme case, the market would price it more as "net cash + failed pipeline discount."

【Tracking Metrics】 I will focus on these 8 items going forward:

• The FDA decision and launch pace for mRNA-1010.

• Real uptake of mCOMBRIAX in the EU, not just approval.

• Changes in mNEXSPIKE's U.S. market share.

• Whether 2026-2027 revenue growth is delivered.

• The pace of improvement in operating cash flow and free cash flow in 2026-2028.

• Whether ending cash and investments stay above $4.5-5.0 billion.

• intismeran Phase 3 melanoma results and commercialization path.

• Any new major intellectual-property litigation, regulatory policy, or vaccination recommendation changes.

【Signals That Trigger Reassessment】

• Flu or combination vaccine approval is delayed or fails.

• Phase 3 melanoma results fall short of expectations.

• Revenue does not improve in 2026-2027 while cash continues to fall rapidly.

• The company is forced into obvious equity issuance or high-cost financing.

• Major U.S. vaccine policies continue to work against mRNA commercialization.

【Final Recommendation】 If you are a balanced but conservative long-term investor, my recommendation is restrained: put Moderna on the watchlist, not in the core portfolio. It may certainly become an excellent investment if flu, combination vaccines, and cancer vaccines all bloom, but today's price does not give you a thick enough buffer for mistakes. What truly attracts a long-term business owner is not only "the technology is strong," but "even if I am somewhat wrong, I will not lose much"; by that standard, MRNA does not yet qualify.

【Open Questions and Limitations】 I deliberately used a conservative framework, so I did not use sell-side consensus expectations to raise the valuation; at the same time, the company does not separately disclose "maintenance capex," so Owner Earnings can only be approximated with conservative assumptions; in addition, the commercial value of cancer vaccines still comes more from clinical prospects than verified profits, so any valuation should be treated as a range judgment, not a precise number.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.